Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis

Annals of Clinical and Laboratory Science

Volumn 31, Issue 4, 2001, Pages 325-348

  Fosslien, E ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiogenesis; Cancer; Celecoxib; COX 2; Hypoxia; iNOS; Microvascular density; NSAIDs; p53; PGE2; Rofecoxib; TGF ; TSP 1; VEGF

Indexed keywords

ANGIOSTATIN; CD31 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; ENDOGLIN; HAPTOGLOBIN; METALLOPROTEINASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROTEIN P53; ROFECOXIB; THROMBOSPONDIN 1; TILMACOXIB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; COLON CANCER; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IN VITRO STUDY; MICROVASCULARIZATION; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; STROMA CELL; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER;

ANIMALS; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

MUS MUSCULUS;

EID: 0034769736     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (169)

1. Understanding angiogenesis and its clinical applications
2. Arachidonic acid and prostaglandins, inflammation and oncology
3. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells
4. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis
5. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia
6. Molecular pathology of cyclooxygenase-2 in neoplasia
7. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients
8. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
9. The role of cyclooxygenases in inflammation, cancer, and development
10. The contributions of cyclooxygenase-2 to tumor angiogenesis
11. A putative role for oncogenes in trophoblast invasion?
12. Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis
13. Malformations of angiogenesis in the low differentiated human carcinomas. Immunohistochemical study
14. Angiogenesis and implantation
15. Implantation in the baboon: Endometrial responses
16. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
17. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice
18. Strain dependency of TGFbeta function during embryo-genesis
19. Expression and regulation of vascular endothelial growth factor in a first trimester trophoblast cell line
20. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
21. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus
22. A study for functions of prostaglandin E receptor EP4 subtype by analysing knockout mice
23. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2
24. Transforming growth factor-beta protein and messenger RNA expression is increased in the closing ductus arteriosus
25. Effect of aging on human protein composition. I. One-dimensional polyacrylamide gel electrophoretic analysis of tissue extracts
26. Effect of aging on human aortic protein composition. II. Two-dimensional polyacrylamide gel electrophoretic analysis of tissue extracts
27. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats
28. Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats
29. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation
30. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants
31. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants
32. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2
33. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin
34. Escape from immunological surveillance in blastocyst implantation and cancer
35. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
36. Angiogenesis in breast cancer: The role of transforming growth factor beta and CD 105
37. The biochemistry of cancer dissemination
38. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis
39. Tumor angiogenesis
40. Dynamic contrast-enhanced MRI and fractal characteristics of percolation clusters in two-dimensional tumor blood perfusion
41. COX-2 is expressed in human pulmonary, colonic, and mammary tumors
42. Cyclooxygenase-2 is overexpressed in human cervical cancer
43. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy
44. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma
45. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer
46. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment
47. Expression of cyclooxygenase-2 in prostate carcinoma
48. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate
49. Expression of cyclooxygenase 2 in human malignant melanoma
50. Cox-2 expression in retinoblastoma
51. Angiogenesis and p53 protein expression in breast cancer: Prognostic roles and interrelationships
52. Predication of axillary lymph node metastasis by intravenous digital subtraction angiography in breast cancer, its correlation with microvascular density
53. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors
54. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer
55. Expression of vascular endothelial growth factor in renal cell carcinomas
56. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma
57. Immunohistochemical localization of vascular endothelial growth factor in esophageal cancer
58. Vascular endothelial growth factor expression in malignant melanoma: Prognostic versus diagnostic usefulness
59. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer
60. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
61. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma
62. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma
63. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival
64. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma
65. Structure, hormonal regulation, and identification of the interleukin-6-and dexamethasone-responsive element of the rat haptoglobin gene
66. Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis
67. Characterization of cancer cell lines established from two human metastatic breast cancers
68. Cancer cells release a covalent complex containing disulfidelinked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains
69. Relative importance of quantifying area and vascular patterns in uveal melanomas
70. Fractal characteristics of tumor vascular architecture during tumor growth and regression
71. Angiogenic factors expressed by human prostatic cell lines: Effect on endothelial cell growth in vitro
72. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas
73. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
74. Expression of vascular endothelial growth factor in human hepatocellular carcinoma
75. Breast cancer angiogenesis - New approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting
76. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts
77. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP
78. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases
79. Host cyclooxygenase-2 modulates carcinoma growth
80. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
81. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase- 1 overexpression
82. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
83. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
84. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells
85. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis
86. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells
87. Subversion of immune system by tumor cells and role of prostaglandins
88. Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis
89. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis
90. Molecular biology of the VEGF and the VEGF receptor family
91. Human orf and erythema multiforme
92. Viral vascular endothelial growth factor plays a critical role in orf virus infection
93. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12
94. DNA amplification on chromosome 6p 12 in non small cell lung cancer detected by arbitrarily primed polymerase chain reaction
95. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase
96. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells
97. The effect of age on cyclooxygenase-2 gene expression: NF-kappaB activation and IkappaBalpha degradation
98. The biochemistry of aging
99. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation
100. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin
101. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts
102. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
103. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma
104. Expression of thrombospondin-1 in pancreatic carcinoma: Correlation with microvessel density
105. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells
106. Thrombospondin-1, PECAM-1, and regulation of angiogenesis
107. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity
108. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
109. Alterations in tumour suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells
110. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells
111. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice
112. A novel assay of angiogenesis in the quail chorioallantoic membrane: Stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection
113. The establishment and maintenance of curvature: A morphodynamic hypothesis
114. Activation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology
115. Thrombospondin 1 does not activate transforming growth factor beta-1 in a chemically defined system or in smooth-muscle-cell cultures
116. Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma
117. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells
118. Thrombospondin- 1 (TSP-1) promotes the invasive properties of human breast cancer
119. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization
120. Coordinate regulation of cyclooxygenase-2 and TGF-betal in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors
121. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis
122. TGF-beta1 in colonic neoplasia: A genetic molecular and immunohistochemical study
123. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis
124. TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis
125. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice
126. Human uterine leiomyoma cells: Growth responses to epidermal growth factor and transforming growth factor beta
127. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis
128. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis
129. Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia
130. Blockade of TGF-beta by in vivo gene transfer of a soluble TGF-beta type II receptor in the muscle inhibits corneal opacification, edema and angiogenesis
131. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice
132. Defective angiogenesis in mice lacking endoglin
133. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer
134. Endoglin expression as a measure of microvessel density in cervical cancer
135. Regulation ofeicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester
136. Expression of TGF-alpha and EGFR in breast cancer and its relation to angiogenesis
137. Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype
138. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line
139. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor
140. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells
141. Von Hippel-Lindau syndrome: Target for anti-vascular endothelial growth factor (VEGF) receptor therapy
142. Up-regulation of hypoxia-inducible factors HIF-1 alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
143. Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53
144. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
145. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
146. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran
147. Increased angiogenesis in the uterine cervix associated with human papillomavirus infection
148. Oncogenes and tumor angiogenesis: The HPV-16 E6 onco-protein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner
149. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells
150. Synergistic induction of cyclooxygenase-2 by transforming growth factor-betal and epidermal growth factor inhibits apoptosis in epithelial cells
151. Biphasic effects of transforming growth factor-beta on the production of osteoclast-like cells in mouse bone marrow cultures: The role of prostaglandins in the generation of these cells
152. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: Synergy with interleukin-1beta
153. Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M
154. Oncostatin M induces angiogenesis in vitro and in vivo
155. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization
156. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers
157. Circulating angiogenesis regulators in cancer patients
158. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media
159. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation
160. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system
161. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors
162. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
163. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
164. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. (Celecoxib Long-term Arthritis Safety Study)
165. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
166. Cyclooxygenas-2: A major therapeutic advance?
167. Cyclooxygenase 2 and the kidney
168. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo